Horn & Co. represented Nanosynex Ltd. in the deal.
Qualigen Therapeutics, Inc. has completed the acquisition of a majority stake in NanoSynex Ltd., an Israeli-based developer of next generation diagnostics technology.
Qualigen Therapeutics, Inc. is a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics.
The Horn & Co. team was led by Uri Dotan (Picture) and Shiran Glantz.
Involved fees earner: Uri Dotan – Horn & Co. Law; Shiran Glantz – Horn & Co. Law;
Law Firms: Horn & Co. Law;
Clients: NanoSynex;
